{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T13:00:30Z","timestamp":1776258030702,"version":"3.50.1"},"reference-count":51,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81272253"],"award-info":[{"award-number":["81272253"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Gastro and Hepatol"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and Aim<\/jats:title><jats:p>Various all\u2010oral direct\u2010acting antiviral (DAA) regimens are being widely used in the treatment of human immunodeficiency virus (HIV)\/hepatitis C virus (HCV) co\u2010infected patients; however, the comparative efficacy and safety of different types and combinations of DAAs are not completely clear. There is still a lack of integration of evidence for optimized therapies for HIV\/HCV co\u2010infection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a systematic literature search in several databases up to January 1, 2020. All the studies that reported the sustained virologic response (SVR) and adverse events of DAAs in HIV\/HCV co\u2010infected patients were included. The Bayesian Markov Chain Monte Carlo method was used for the pooled estimates of network meta\u2010analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified 33 eligible articles with 7 combinations of all\u2010oral DAAs for the analyses of efficacy and safety. Grazoprevir\u2013elbasvir\u00a0\u00b1\u00a0ribavirin (GZR\/EBR\u00a0\u00b1\u00a0RBV: 95.6%; 95% CrI, 91.7\u201398.1%), ombitasvir\/paritaprevir\/ritonavir and dasabuvir\u00a0\u00b1\u00a0ribavirin (3D\u00a0\u00b1\u00a0RBV: 95.3%; 95% CrI, 93.4\u201396.9%), sofosbuvir\u2013ledipasvir\u00a0\u00b1\u00a0ribavirin (SOF\/LDV\u00a0\u00b1\u00a0RBV: 95.2%; 95% CrI, 93.7\u201396.6%), and sofosbuvir\u2013daclatasvir\u00a0\u00b1\u00a0ribavirin (SOF\/DCV\u00a0\u00b1\u00a0RBV: 94.8%; 95% CrI, 92.5\u201396.6%) were the most effective combinations for HIV\/HCV co\u2010infected patients, with SVR rates of approximately 94% and above while severe adverse events were rare. However, the SVR rates of sofosbuvir\u2013ribavirin (SOF\/RBV) and sofosbuvir\u2013simeprevir\u00a0\u00b1\u00a0ribavirin (SOF\/SMV\u00a0\u00b1\u00a0RBV) both failed to reach 90%, and the incidences of adverse events were higher than 5%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Efficacy and safety of all\u2010oral DAAs were in prospect for HIV\/HCV co\u2010infection patients. GZR\/EBR\u00a0\u00b1\u00a0RBV was the optimal combination recommended for HIV\/HCV co\u2010infected patients based on the excellent treatment effects and insignificant adverse events.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jgh.15051","type":"journal-article","created":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T20:09:38Z","timestamp":1586030978000},"page":"1477-1487","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and safety of direct acting antiviral regimens for hepatitis C virus and human immunodeficiency virus co\u2010infection: systematic review and network meta\u2010analysis"],"prefix":"10.1111","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3913-8691","authenticated-orcid":false,"given":"Yi\u2010Xiang","family":"Zheng","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Key Laboratory of Viral Hepatitis of Hunan, Xiangya Hospital Central South University  Changsha China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu\u2010Juan","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Health Statistics, School of Public Health Central South University  Changsha China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying\u2010hui","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Key Laboratory of Viral Hepatitis of Hunan, Xiangya Hospital Central South University  Changsha China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue\u2010Gong","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Key Laboratory of Viral Hepatitis of Hunan, Xiangya Hospital Central South University  Changsha China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,4,15]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27259"},{"key":"e_1_2_7_3_1","first-page":"24","article-title":"Use of daclatasvir in HCV\/HIV\u2010coinfected patients in a real\u2010life setting","volume":"19","author":"Bonora S","year":"2017","journal-title":"AIDS Rev."},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.217166"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-9-201305070-00604"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-052915-015720"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ438"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsb1609216"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1445-2197.2003.02748.x"},{"key":"e_1_2_7_11_1","unstructured":"WellsGA SheaB O'ConnellD et al.The Newcastle\u2010Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta\u2010analyses."},{"key":"e_1_2_7_12_1","unstructured":"(CDER) USDoHaHSFaDACfDEaR.Chronic hepatitis C virus infection: developing direct\u2010acting antiviral drugs for treatment guidance for industry. In: FDA.https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM225333.pdf 2017."},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X13485155"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1204"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.7734"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofv168"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62483-1"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501315"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.1373"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(15)00114-9"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61793-1"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.1328"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503153"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw119"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw203"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw567"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/15284336.2016.1248625"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001020"},{"issue":"5","key":"e_1_2_7_29_1","first-page":"680","article-title":"Ombitasvir\/paritaprevir\/ritonavir and dasabuvir combination treatment in patients with HIV\/HCV co\u2010infection: results of an Italian compassionate use program","volume":"64","author":"Massimo A","year":"2016","journal-title":"Clinical Infectious Diseases"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3108"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix111"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001342"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12429"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.02.012"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx154"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-016-1162-y"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix260"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw597"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29814"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.5009\/gnl18004"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-018-9891-9"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1080\/15284336.2018.1436637"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12571"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2019.05.005"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz100"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0225061"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14936"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(17)30003-1"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ1222"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27950"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2016.10.034"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2015.0004"}],"container-title":["Journal of Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjgh.15051","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jgh.15051","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jgh.15051","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jgh.15051","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T15:47:25Z","timestamp":1693928845000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jgh.15051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,15]]},"references-count":51,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1111\/jgh.15051"],"URL":"https:\/\/doi.org\/10.1111\/jgh.15051","archive":["Portico"],"relation":{},"ISSN":["0815-9319","1440-1746"],"issn-type":[{"value":"0815-9319","type":"print"},{"value":"1440-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,15]]},"assertion":[{"value":"2019-08-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}